Thompson DC - Search Results

1

Assessment of the metabolism and intrinsic reactivity of a novel catechol metabolite.

Hutzler JM, Melton RJ, Rumsey JM, Thompson DC, Rock DA, Wienkers LC. Hutzler JM, et al. Among authors: thompson dc. Chem Res Toxicol. 2008 May;21(5):1125-33. doi: 10.1021/tx700429v. Epub 2008 Apr 12. Chem Res Toxicol. 2008. PMID: 18407675

2

Peptide-based in vitro assay for the detection of reactive metabolites.

Mitchell MD, Elrick MM, Walgren JL, Mueller RA, Morris DL, Thompson DC. Mitchell MD, et al. Among authors: thompson dc. Chem Res Toxicol. 2008 Apr;21(4):859-68. doi: 10.1021/tx700344m. Epub 2008 Mar 28. Chem Res Toxicol. 2008. PMID: 18370411

3

Role of metabolism in drug-induced idiosyncratic hepatotoxicity.

Walgren JL, Mitchell MD, Thompson DC. Walgren JL, et al. Among authors: thompson dc. Crit Rev Toxicol. 2005 Apr-May;35(4):325-61. doi: 10.1080/10408440590935620. Crit Rev Toxicol. 2005. PMID: 15989140 Review.

4

Evaluation of two novel peptide safety markers for exocrine pancreatic toxicity.

Walgren JL, Mitchell MD, Whiteley LO, Thompson DC. Walgren JL, et al. Among authors: thompson dc. Toxicol Sci. 2007 Mar;96(1):184-93. doi: 10.1093/toxsci/kfl190. Epub 2006 Dec 14. Toxicol Sci. 2007. PMID: 17169977

5

Identification of novel peptide safety markers for exocrine pancreatic toxicity induced by cyanohydroxybutene.

Walgren JL, Mitchell MD, Whiteley LO, Thompson DC. Walgren JL, et al. Among authors: thompson dc. Toxicol Sci. 2007 Mar;96(1):174-83. doi: 10.1093/toxsci/kfl189. Epub 2006 Dec 14. Toxicol Sci. 2007. PMID: 17169978

6

Application of proteomic technologies in the drug development process.

Walgren JL, Thompson DC. Walgren JL, et al. Among authors: thompson dc. Toxicol Lett. 2004 Apr 1;149(1-3):377-85. doi: 10.1016/j.toxlet.2003.12.047. Toxicol Lett. 2004. PMID: 15093284 Review.

7

Novel metabolic bioactivation mechanism for a series of anti-inflammatory agents (2,5-diaminothiophene derivatives) mediated by cytochrome p450 enzymes.

Hu Y, Yang S, Shilliday FB, Heyde BR, Mandrell KM, Robins RH, Xie J, Reding MT, Lai Y, Thompson DC. Hu Y, et al. Among authors: thompson dc. Drug Metab Dispos. 2010 Sep;38(9):1522-31. doi: 10.1124/dmd.110.032581. Epub 2010 Jun 7. Drug Metab Dispos. 2010. PMID: 20530221

8

Proteomics: recent applications and new technologies.

Elrick MM, Walgren JL, Mitchell MD, Thompson DC. Elrick MM, et al. Among authors: thompson dc. Basic Clin Pharmacol Toxicol. 2006 May;98(5):432-41. doi: 10.1111/j.1742-7843.2006.pto_391.x. Basic Clin Pharmacol Toxicol. 2006. PMID: 16635100 Free article. Review.

9

Combined use of pharmacokinetic modeling and a steady-state delivery approach allows early assessment of IkappaB kinase-2 (IKK-2) target safety and efficacy.

Chiang PC, Kishore NN, Thompson DC. Chiang PC, et al. Among authors: thompson dc. J Pharm Sci. 2010 Mar;99(3):1278-87. doi: 10.1002/jps.21909. J Pharm Sci. 2010. PMID: 19743500

10

A novel, highly selective, tight binding IkappaB kinase-2 (IKK-2) inhibitor: a tool to correlate IKK-2 activity to the fate and functions of the components of the nuclear factor-kappaB pathway in arthritis-relevant cells and animal models.

Mbalaviele G, Sommers CD, Bonar SL, Mathialagan S, Schindler JF, Guzova JA, Shaffer AF, Melton MA, Christine LJ, Tripp CS, Chiang PC, Thompson DC, Hu Y, Kishore N. Mbalaviele G, et al. Among authors: thompson dc. J Pharmacol Exp Ther. 2009 Apr;329(1):14-25. doi: 10.1124/jpet.108.143800. Epub 2009 Jan 23. J Pharmacol Exp Ther. 2009. PMID: 19168710

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

261 results

Search Page

Filters